At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,149 enrolled
Drug / intervention
Mirabegron +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder
In Brief
A Phase 3 clinical trial evaluating Mirabegron and Placebo for Urinary Bladder, Overactive. Completed, enrolled 2,149 participants across 125 sites in 2 countries.
Detailed Summary
The study is intended to test the efficacy, safety and tolerability of two doses of mirabegron against placebo to treat patients with symptoms of overactive bladder
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Bladder, Overactive
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedApr 2008
Primary CompletionApr 2009
TodayJul 2026
First PostedApr 21, 2008
Enrollment StartMar 28, 2008
Primary CompletionApr 22, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.2 years ago
Interventions
Mirabegrondrug
Oral
Placebodrug
Oral